BENLYSTA
Clinical safety rating
cautionComprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).
Comprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).
Systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive disease receiving standard therapyLupus nephritis (in combination with standard therapy)
Belimumab is a human IgG1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS, also known as BAFF), inhibiting its activity. BLyS is a cytokine that promotes B-cell survival and differentiation. By binding BLyS, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
| Metabolism | Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation. |
| Excretion | Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways. |
| Half-life | Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing. |
| Protein binding | Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin. |
| Volume of Distribution | Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space. |
| Bioavailability | SC: ~82% relative to IV; IV: 100%. |
| Onset of Action | IV: Improvement in disease activity observed as early as 4 weeks; SC: Onset similar, with clinical benefit seen by 8 weeks. |
| Duration of Action | Sustained suppression of disease activity with monthly IV (or weekly SC) dosing; effects persist for several weeks after last dose due to long half-life. |
| Molecular Weight | 147 |
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl >=30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or ESRD. Use caution and consider benefit-risk. |
| Liver impairment | No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class. |
| Pediatric use | In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years. |
| Geriatric use | No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions. |
| 1st trimester | Limited human data; animal studies show no evidence of fetal harm at therapeutic doses, but risk cannot be ruled out. Use only if clearly needed. |
| 2nd trimester | Limited human data; risk of preterm birth and low birth weight reported in some studies. Consider maternal benefit vs fetal risk. |
| 3rd trimester | Limited human data; theoretical risk of hematologic abnormalities (e.g., neutropenia) in neonate due to IgG transfer. Monitor neonate for infections. |
Clinical note
Comprehensive clinical and safety monograph for BENLYSTA (BENLYSTA).
| Placental transfer | Belimumab is an IgG monoclonal antibody and undergoes placental transfer, especially during the third trimester. Fetal serum levels may approach maternal levels at term. |
| Breastfeeding | Belimumab is a human IgG1 monoclonal antibody, likely present in breast milk in low amounts. No data on systemic absorption in infants; consider benefit of breastfeeding vs risk of potential adverse effects. Use caution. |
| Lactation Rating | L3 |
| Teratogenic Risk | First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as IgG crosses placenta after 13 weeks gestation. Third trimester: IgG actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk). |
| Fetal Monitoring | Monitor maternal complete blood count with differential monthly; fetal ultrasound for growth assessment if prolonged exposure. Neonatal evaluation for infection risk and B-cell count at birth. |
| Fertility Effects | No specific data in humans; animal studies showed no adverse effects on male or female fertility. Theoretical potential for immunomodulation to impair ovarian reserve or spermatogenesis, but not established. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
History of anaphylaxis to belimumab or any excipient
| Precautions | Hypersensitivity reactions including anaphylaxis, Infusion reactions, Increased risk of serious infections, including tuberculosis and opportunistic infections, Malignancy risk (potential), Hypogammaglobulinemia, Depression and suicidality |
| Food/Dietary | No known food interactions. May be taken without regard to meals. |
| Clinical Pearls | BENLYSTA (belimumab) is a BLyS-specific inhibitor for adjunctive therapy in active systemic lupus erythematosus (SLE). Monitor for hypersensitivity reactions during infusion. Do not administer with live vaccines. Contraindicated in severe active lupus nephritis or severe active CNS lupus. Renal function monitoring required due to potential for progressive multifocal leukoencephalopathy (PML) risk. |
| Patient Advice | Report any signs of allergic reaction during or after infusion immediately. · Avoid live vaccines during treatment and for at least 30 days after stopping. · Inform doctor of any new or worsening neurological symptoms. · Use effective contraception during therapy and for 4 months after last dose. · Do not stop or change dose without consulting your rheumatologist. |
Loading safety data…